about
Systematic review: fatigue in inflammatory bowel disease.Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: 'a cocktail best avoided, not stirred'.Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease.Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease.Inflammatory bowel disease serology in Asia and the West.Un-promoted issues in inflammatory bowel disease: opportunities to optimize care.The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience.Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status.Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis.Maintaining muscle strength in Crohn's disease: can a vitamin D daily keep muscle loss away?Chronic pain in inflammatory bowel disease: characteristics and associations of a hospital-based cohort.Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome.A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease.Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care.The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea.Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change.Predicting Response after Infliximab Salvage in Acute Severe Ulcerative Colitis.Sleep and physical activity measured by accelerometry in Crohn's disease.Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study.Poor predictive value of breath hydrogen response for probiotic effects in IBS.Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing.Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based auditAre All Symptoms in Patients in IBD Due to Occult Inflammation?Gastrointestinal: acute haemorrhage from a Dieulafoy lesion within a gastric diverticulum managed endoscopicallyLow-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel diseaseFaecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort studyCharacterization of ulcerative colitis-associated constipation syndrome (proximal constipation)A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease
P50
Q33574005-8BFEBE9B-23C2-481C-93E7-4EC9F4884E4BQ34028028-D7D6381E-C668-4003-9DC8-5961A415D97BQ35044905-7D3A7098-2C2B-4C2E-B8F4-18F22D7E4E15Q35065914-98305A29-44B4-47AC-9BCE-908C69CF015FQ37208122-295D83DE-287B-4D05-B3ED-CA6D90376DF0Q37619661-363FC574-9735-47C2-A3C8-7C8A1FBCC135Q37814558-82EAE032-5D5E-4A6C-ABC9-EA26DA597E2BQ37826807-85BD8545-0F01-4959-99C9-CF4C7627737FQ38724227-CA80358C-2542-453A-8762-003EF8A0E1B9Q44212857-E5C057EC-E402-4832-AF66-EFA7CB83EFB7Q44410017-D755EF84-3689-4F6D-B1E7-0661833F31ABQ45221590-1589D696-4198-4EB8-B5F4-530F1BB36CFAQ45349135-47867AE6-4569-4EE7-800C-55D121FBA87EQ45787607-B6F86C38-CFC9-40BE-80EF-C4AF4B52D3ECQ46047240-9FE1C523-35BA-462D-88B3-B6B0306E263AQ46416214-0A208A0E-F8BB-4B97-9BB0-CFAE104BC27AQ47269316-FAA8FE0E-64F3-482F-A8E1-DB55954C2617Q47987094-097447E9-B411-47CF-B20B-5C2DBC075B29Q48124857-BD5DA94D-904F-437C-AE4A-65197FD1650EQ48168879-5AE8D9D9-ED73-4C62-8C52-9F6DA0B54FF5Q51284388-6B3B27B3-BAB5-4414-A4E3-8B6FED6A4385Q57455116-6A83AD86-6C24-451E-8325-215D355D9837Q57789396-68C059DA-1EC1-4FCD-B5FE-6CF1D0FDF480Q57789433-D53E7095-D0C2-494D-90E3-D4F822A1DF53Q82211402-31029956-678F-44F7-85EC-A4E3F3F7FE92Q88015565-E474816B-DEBD-4793-91F8-47423CF795E5Q89371025-14D8A456-7F66-45B5-A28F-F8975BB7D9C4Q93355918-78659152-477E-40F6-B367-5B0A647CC116Q94604599-612AD304-D805-4B80-ADBC-ED77BAC42E03
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel R van Langenberg
@ast
Daniel R van Langenberg
@en
Daniel R van Langenberg
@es
Daniel R van Langenberg
@nl
Daniel R van Langenberg
@sl
type
label
Daniel R van Langenberg
@ast
Daniel R van Langenberg
@en
Daniel R van Langenberg
@es
Daniel R van Langenberg
@nl
Daniel R van Langenberg
@sl
prefLabel
Daniel R van Langenberg
@ast
Daniel R van Langenberg
@en
Daniel R van Langenberg
@es
Daniel R van Langenberg
@nl
Daniel R van Langenberg
@sl
P106
P1153
35346141000
P21
P31
P496
0000-0003-3662-6307